Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection

Lewis Beer, Sarah Inglis, Amy Malaguti, Christopher Byrne, Christian Sharkey, Emma Robinson, Kirsty Gillings, Andrew Radley, Adrian Hapca, Brian Stephens, John Dillon, Lewis Beer, Sarah Inglis, Amy Malaguti, Christopher Byrne, Christian Sharkey, Emma Robinson, Kirsty Gillings, Andrew Radley, Adrian Hapca, Brian Stephens, John Dillon

Abstract

Hepatitis C virus (HCV) treatment in people who inject drugs (PWID) is delivered within settings frequented by PWID, such as needle and syringe programs (NSP). The optimal direct-acting antiviral (DAA) dispensing regimen among NSP clients is unknown. This study compared cures (Sustained virologic response 12 weeks post-treatment, [SVR12 ]) across three dispensing schedules to establish non-inferiority of fortnightly dispensing versus directly observed therapy. The ADVANCE HCV study was a randomized, unblinded trial, recruiting PWID attending NSP in Tayside, Scotland, between January 2018 and November 2019. HCV-positive participants were randomized to receive DAAs via directly observed therapy, fortnightly provision or fortnightly provision with psychological intervention. A modified intention to treat analysis was used to identify differences in cures between the three treatment regimes. The study was registered with clinicaltrials.gov; NCT03236506. A total of 110 participants completed the study. 33 participants received directly observed therapy, with 90.91% SVR12 ; 37 received fortnightly provision, with 86.49% SVR12 and 40 received fortnightly provision and psychological intervention at treatment initiation, with 92.50% SVR12 . Analysis showed no significant difference in SVR12 (p = 0.67). This study did not demonstrate a statistically significant difference in cure rate between groups. This provides evidence of the non-inferiority of fortnightly dispensing of direct-acting antivirals (DAAs) compared to directly observed therapy among PWID. It suggests that tight control of adherence through directly observed therapy dispensing of DAAs among this population offers no therapeutic advantage. Therefore, less restrictive dispensing patterns can be used, tailored to patient convenience.

Keywords: direct-acting antivirals; hepatitis c; needle and syringe programs; randomized controlled trial.

© 2022 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Consort diagram. aDNIT, did not initiate treatment; bWD, withdrawn; cDOT, direct observed treatment; dw/Psych Int, with psychological intervention; eSVR12, test for sustained viral response at least 12 weeks post treatment
FIGURE 2
FIGURE 2
Participant retention

References

    1. World Health Organisation . Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections 2019: Accountability for the Global Health Sector Strategies, 2016–2021. World Health Organization; 2019.
    1. World Health Organisation . Combating Hepatitis B and C to Reach Elimination by 2030. 2016; Available from:
    1. Grebely J, Larney S, Peacock A, et al. Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150‐166.
    1. D'Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct‐acting antivirals: the endgame for hepatitis C? Curr Opin Virol. 2017;24:31‐37.
    1. Falade‐Nwulia O, Suarez‐Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct‐acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637‐648.
    1. Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct‐acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754‐767.
    1. Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C, International Network on Hepatitis in Substance Users . Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy. 2019;72:1‐10.
    1. Wade AJ, Doyle JS, Gane E, et al. Outcomes of treatment for hepatitis C in primary care, compared to hospital‐based care: a randomized, controlled trial in people who inject drugs. Clin Infect Dis. 2020;70(9):1900‐1906.
    1. Trooskin SB, Dore G, Kostman J. We must do better: addressing HCV treatment barriers in persons who inject drugs in the United States. J Infect Dis. 2020;222(Suppl 9):S773‐s781.
    1. Pourmarzi D, Smirnov A, Hall L, Thompson H, FitzGerald G, Rahman T. Enablers and barriers for the provision of community‐based HCV treatment: a case study of a real‐world practice. J Viral Hepat. 2020;27(5):484‐496.
    1. Chikovani I, Ompad DC, Uchaneishvili M, et al. On the way to hepatitis C elimination in the republic of Georgia‐barriers and facilitators for people who inject drugs for engaging in the treatment program: a formative qualitative study. PLoS One. 2019;14(4):e0216123.
    1. Wolfe D, Luhmann N, Harris M, et al. Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy. 2015;26(11):1072‐1080.
    1. Graham CS. The current status of US and global access to direct‐acting antiviral regimens for hepatitis C virus infection. Clin Liver Dis. 2020;16(1):16‐19.
    1. Marshall AD, Pawlotsky JM, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – one step closer to eliminating HCV as a major public health threat. J Hepatol. 2018;69(5):1188‐1196.
    1. Coffin PO, Santos GM, Behar E, et al. Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir‐sofosbuvir among people who inject drugs. PLoS One. 2019;14(6):e0217471.
    1. Hickman M, Dillon JF, Elliott L, et al. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) ‐ a natural experiment (protocol). BMJ Open. 2019;9(9):e029538.
    1. Radley A, Tait J, Dillon JF. DOT‐C: a cluster randomised feasibility trial evaluating directly observed anti‐HCV therapy in a population receiving opioid substitute therapy from community pharmacy. Int J Drug Policy. 2017;47:126‐136.
    1. Radley A, de Bruin M, Inglis SK, et al. Clinical effectiveness of pharmacist‐led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster‐randomised trial. Lancet Gastroenterol Hepatol. 2020;5(9):809‐818.
    1. Byrne C, Radley A, Inglis SK, et al. Reaching mEthadone users attending community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV). BMJ Open. 2020;10(8):e036501.
    1. Schulkind J, Stephens B, Ahmad F, et al. High response and re‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepat. 2018;26:519‐528.
    1. Butsashvili M, Kamkamidze G, Kajaia M, et al. Integration of hepatitis C treatment at harm reduction centers in Georgia‐findings from a patient satisfaction survey. Int J Drug Policy. 2020;84:102893.
    1. Morris L, Smirnov A, Kvassay A, et al. Initial outcomes of integrated community‐based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors' health network. Int J Drug Policy. 2017;47:216‐220.
    1. Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017;47:209‐215.
    1. Treloar C, Hopwood M, Cama E, et al. Evaluation of the deadly liver mob program: insights for roll‐out and scale‐up of a pilot program to engage aboriginal Australians in hepatitis C and sexual health education, screening, and care. Harm Reduct J. 2018;15(1):5.
    1. Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196‐201.
    1. Inglis SK, Beer LJ, Byrne C, et al. Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: a direct obserVed therApy versus fortNightly CollEction study for HCV treatment‐ADVANCE HCV protocol study. BMJ Open. 2019;9(8):e029516.
    1. Braun N, Debener S, Spychala N, et al. The senses of agency and ownership: a review. Front Psychol. 2018;9:535.
    1. Fraser S. The chronotope of the queue: methadone maintenance treatment and the production of time, space and subjects. Int J Drug Policy. 2006;17(3):192‐202.
    1. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information‐motivation‐behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462‐473.
    1. Munro S, Lewin S, Swart T, Volmink J. A review of health behaviour theories: how useful are these for developing interventions to promote long‐term medication adherence for TB and HIV/AIDS? BMC Public Health. 2007;7:104.
    1. Joe GW et al. Effectiveness of node‐link mapping enhanced counseling for opiate addicts: a 12‐month posttreatment follow‐up. J Nerv Ment Dis. 1997;185(5):306‐313.
    1. Horne R, Glendinning E, King K, et al. Protocol of a two arm randomised, multi‐Centre, 12‐month controlled trial: evaluating the impact of a cognitive Behavioural therapy (CBT)‐based intervention supporting UPtake and adherence to antiretrovirals (SUPA) in adults with HIV. BMC Public Health. 2019;19(1):905.
    1. Linas BP, Barter DM, Leff JA, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One. 2014;9(5):e97317.
    1. Grebely J, Hajarizadeh B, Dore GJ. Direct‐acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14(11):641‐651.
    1. Altice FL, Maru DSR, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self‐administered therapy among HIV‐infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45(6):770‐778.
    1. Radley A, van der Pol M, Dillon JF. Application of a discrete choice experiment approach to support the design of a hepatitis C testing service in primary care. Int J Drug Policy. 2019;65:1‐7.
    1. Radley A, Melville K, Easton P, Williams B, Dillon JF. Standing outside the junkie Door'‐service users' experiences of using community pharmacies to access treatment for opioid dependency. J Public Health (Oxf). 2017;39(4):846‐855.
    1. Byrne C, et al. Delivering HCV Elimination: Outcomes of Rapid Regional Scale‐up of Hepatitis C Virus Direct Acting Antiviral Treatment among People Who Inject Drugs in NHS Tayside 2017–2020. 2021.
    1. Lazarus JV, Picchio CA, Guy D, et al. Hepatitis C standards of care: a review of good practices since the advent of direct‐acting antiviral therapy. Clin Res Hepatol Gastroenterol. 2021;45(2):101564.
    1. Soyka M. Novel long‐acting buprenorphine medications for opioid dependence: current update. Pharmacopsychiatry. 2021;54(1):18‐22.
    1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889‐1898.
    1. EASL recommendations on treatment of hepatitis C: final update of the series(☆). J Hepatol. 2020;73(5):1170‐1218.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever